Studies on the use of carbamazepine in pregnant women have demonstrated exposure of the fetus to the drug and its metabolites to be teratogenic and is associated with the development of spina bifida, neurodevelopmental problems, craniofacial defects, cardiovascular malformations, hypospadias, and developmental delays.
Studies on the use of carbamazepine in pregnant women have demonstrated exposure of the fetus to the drug. This was to be teratogenic. Studies on the use of carbamazepine in pregnant women have demonstrated exposure of the fetus to its metabolites. This was to be teratogenic. Studies on the use of carbamazepine in pregnant women is associated with the development of spina bifida. Studies on the use of carbamazepine in pregnant women is associated with the development of neurodevelopmental problems. Studies on the use of carbamazepine in pregnant women is associated with the development of craniofacial defects. Studies on the use of carbamazepine in pregnant women is associated with the development of cardiovascular malformations. Studies on the use of carbamazepine in pregnant women is associated with the development of hypospadias. Studies on the use of carbamazepine in pregnant women is associated with the development of developmental delays.